Norwegian Cruise downgrade, Duolingo upgraded: Wall Street's top analyst calls

Norwegian Cruise downgrade, Duolingo upgraded: Wall Street's top analyst calls

Tue, August 18, 2026 at 4:37 PM GMT+3 3 min read

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly.

Top 5 Upgrades:

• DA Davidson upgraded Duolingo (DUOL) to Buy from Neutral with a price target of $160, up from $130. The company's marketing and core monetization changes are underappreciated at current share levels, the firm tells investors in a research note.

• Citi upgraded Bath & Body Works (BBWI) to Buy from Neutral with an unchanged price target of $25. The firm sees a favorable risk/reward into the company's Q2 earnings report.

• KeyBanc upgraded Acadia Realty Trust (AKR) to Overweight from Sector Weight with a $25 price target. The stock's underperformance year-to-date versus the shopping center real estate investment trust group has created an attractive entry point, the firm tells investors in a research note.

• JPMorgan upgraded America Movil (AMX) to Overweight from Neutral with a price target of $32, up from $30. The company's operating trends are "very solid," the firm tells investors in a research note.

• BofA upgraded Americold Realty Trust (COLD) to Neutral from Underperform with a price target of $16, up from $15. Americold's Q2 results showed improvement in physical occupancy and throughput and increased its FY26 AFFO per share guidance by 4c at the midpoint, driven by first half outperformance and continued positive trends, the firm tells investors in a research note.

Top 5 Downgrades:

• Mizuho downgraded Norwegian Cruise Line (NCLH) to Neutral from Outperform with a price target of $17, down from $22. The company is undergoing a turnaround amid "self-inflicted wounds" from accelerated supply, change in customer segmentation, and delays in construction, as well as macro headwinds, the firm says.

• Chardan downgraded EyePoint (EYPT) to Neutral from Buy with a price target of $5, down from $65. The company's LUGANO study missing its Phase 3 non-inferiority primary endpoint, and Chardan says it continues to struggle to determine precisely what drove the miss. H.C. Wainwright and RBC Capital also downgraded EyePoint to Neutral-equivalent ratings.

• Craig-Hallum downgraded Globalstar (GSAT) to Hold from Buy with an unchanged price target of $90. The Amazon (AMZN) takeover remains on track and the arbitrage opportunity has compressed, the firm tells investors in a research note.

• BofA downgraded Autohome (ATHM) to Underperform from Neutral with a price target of $19, down from $20.20. The company is facing "significant" earnings pressure from auto industry headwinds and its business transition, the firm tells investors in a research note.

• JPMorgan downgraded Millicom (TIGO) to Neutral from Overweight with a price target of $105, up from $100. The firm cites increased expectations for the downgrade.

Top 5 Initiations:

• Susquehanna initiated coverage of Travel + Leisure (TNL) with a Positive rating and $95 price target. Travel + Leisure has solid operational momentum, consistent margins, and strong recurring revenue, the firm tells investors in a research note.

• BofA initiated coverage of Kanzhun (BZ) with a Neutral rating and $19 price target. The firm is seeing risk for the company's growth in the second half of the year amid softening of macro conditions since Q2.

• Canaccord initiated coverage of Sunshine Silver Mining (SSMR) with a Speculative Buy rating and $20 price target. Canaccord views the company as a "compelling investment option" for investors looking to gain early exposure to an ultra-high-grade brownfield silver deposit in the U.S. Sunshine has "significant infrastructure supporting a capital-efficient restart and an emerging critical mineral narrative."

• Compass Point initiated coverage of Gorilla Technology (GRRR) with a Buy rating and $44 price target. The firm sees an "earnings inflection" for Gorilla, supported by the current commercial book and additional value potential as the company expands its capacity strategy.

• Wells Fargo initiated coverage of Scribe Therapeutics (SCTX) with an Overweight rating and $60 price target. The firm views the company's ELXR as a "differentiated" epigenetic silencing platform, potentially offering years-long durability without permanent genetic modification.